Tailoring Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
Author:
Affiliation:
1. Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Publisher
SAGE Publications
Subject
Oncology,Hematology,General Medicine
Link
http://journals.sagepub.com/doi/pdf/10.1177/107327480901600203
Reference108 articles.
1. New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
2. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
3. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
4. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase
5. Imatinib use in chronic phase CML in clinical practice: the UNIC study
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment;American Society of Clinical Oncology Educational Book;2017-05
2. Imatinib for treating patients with chronic myelogeneous leukemia;Cochrane Database of Systematic Reviews;2015-10-30
3. Hsp90 — a potential prognostic marker in CML;Blood Cells, Molecules, and Diseases;2013-03
4. A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia;Leukemia Research;2011-08
5. Shooting the messenger: Targeting signal transduction pathways in leukemia and related disorders;Critical Reviews in Oncology/Hematology;2011-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3